BioSpace News Archive

Rafael Pharmaceuticals, Inc. announced that it has crossed the midpoint to its first interim analysis in enrollment for its pivotal Phase 3 clinical trial of CPI-613® for relapsed or refractory acute myeloid leukemia. The multicenter, open-label, randomized pivotal trial is evaluating the efficacy and safety of its lead compound devimistat in combination with high dose cytarabine and mitoxantrone in older patients.

ALASTIN Skincare ®, Inc. - a specialty aesthetics company dedicated to developing and marketing innovative, clinically-tested physician-dispensed skin care products, announces that the Unit

An estimated 37 million American adults are affected by kidney disease but 90% are unaware they even have it.

Orphazyme expects to submit MAA for arimoclomol for NPC to European Medicines Agency in the second half of 2020 Arimoclomol progressing through registrational trials in two additional indications - ALS and sIBM

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host the second webinar in its deep dive series discussing its therapeutic platforms and programs on Friday, July 24 at 10:00 am ET .

Chemomab Ltd ., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces that it has received all necessary regulatory approvals in the UK and Israel , to commence a Phase IIa clinical trial for CM-101 as treatment for Primary Sclerosing Cholan

Sorrel Medical (sorrelmedical.com), an Eitan Group Company, a developer and manufacturer of wearable drug delivery devices, today announced it has entered into a strategic partnership with one of the world’s leading pharmaceutical companies to advance the development and introduction of next-generation wearable drug delivery solutions.

The company announces its first patient enrolled and dosed in a Phase 1/2 clinical trial evaluating its novel IL12 cytokine, DF6002.

Angle Health, a Y Combinator-backed health insurance carrier, today announced that it has closed $4 million in a Series Seed funding round led by Blumberg Capital with participation from Y Combinator, Correlation Ventures, TSVC, Liquid 2 Ventures and several smaller funds and angels.

SLV213, a small molecule drug candidate, inhibits host cell cysteine proteases to block viral entry and has broad antiviral activity against coronaviruses, Ebola viruses, and paramyxoviruses SAN DIEGO--( BUSINESS WIRE )-- Selva Therapeutics, Inc. announced today that the company has raised $3 million in a Series A financing round from private investors. The proceeds of the financing will be used to rapidly advance SLV213 into clinical trials as a l